An experimental drug called aducanumab shows promise in treating Alzheimer's disease, researchers report.
A small clinical trial showed that it significantly reduced toxic plaques in the brains of 165 patients with early-stage Alzheimer's disease, National Public Radio reported Wednesday.
The findings, published in the journal Nature, suggest the drug may slow the loss of memory and thinking in Alzheimer's patients.